Navigation Links
Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon(R)
Date:4/29/2009

m and providing all trial supplies of Nefecon. Pharmalink is responsible for the management of the clinical trials.

About Pharmalink

Pharmalink AB is a privately held Swedish specialty pharma company that develops proprietary pharmaceutical products in fields of unmet medical need. Pharmalink has adopted a reformulation/repurposing strategy and has a vast international network of physicians, biotech companies, CMOs, CROs and specialist consultants. Pharmalink has a track record of introducing more than 15 pharmaceutical products to market. Pharmalink currently has three clinical phase development projects mature for out-licensing: Nefecon(R), an effective treatment of IgA nephropathy; Xepol(R), the first effective treatment of neurology indication post-polio syndrome; and Busulipo(TM), a safer alternative for myeloablation prior to bone marrow transplantation. Pharmalink also seeks to refill its development pipeline by in-licensing.

About Archimedes Pharma

Archimedes Pharma ("Archimedes") is a pan-European specialty pharmaceutical company marketing and selling an expanding portfolio of specialist products to hospital-based prescribers in major European territories.

Archimedes is also developing a robust, high value pipeline of in-house products in pain, Parkinson's disease and critical care. It applies its world-class drug delivery technologies to proven molecules which have yet to achieve their market potential due to their current mode of delivery. This approach reduces the company's development risk, while delivering significant clinical and commercial benefits. The Group's lead development product is NasalFent(R), an innovative and highly differentiated fentanyl citrate nasal spray, for the rapid relief of breakthrough cancer pain.

Archimedes technologies - ChiSys(R), PecSys(TM) and TARGIT(R) - are used in a number of partnered products in late-stage clinic
'/>"/>

SOURCE Pharmalink AB
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharmalink AB Strengthens its Board of Directors and Signals a Strategic Step Towards Late Phase Product Development
2. China Biologic Products Completes Acquisition of 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd.
3. NexBio Completes Clinical Advisory Board for the Advanced Development of DAS181 (Fludase(R)*), a First-In-Class Medicine for Influenza
4. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
5. NeoStem Completes $11 Million Private Placement Financing to Support Expansion Activities in China, Further Development of NeoStems VSEL Technology and Advancement of Medical Tourism Initiatives
6. Gen-Probe Completes Acquisition of Tepnel Life Sciences
7. Transgenomic Completes Licensing Option With Dana-Farber Cancer Institute on Cold-PCR for Enrichment of DNA Mutations
8. SAFC Biosciences(TM) Completes Conversion of Lenexa Media Milling Facility to Animal Component Free
9. Atritech Completes $30 Million Financing
10. Roche Completes Tender Offer for Genentech
11. Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... SC (PRWEB) October 22, 2014 ... of its cardiovascular pharmacogenetics menu, which enables healthcare ... outcomes. With PCLS’s evidence-based results, healthcare providers ... and optimize their therapy, while minimizing risks for ... the U.S., according to the FDA [1] more ...
(Date:10/22/2014)... 2014   Synthetic Biologics, Inc. (NYSE MKT: ... serious infections and diseases, announced today that the U.S. ... Allowance for a composition of matter patent application that ... program, SYN-004. This is Synthetic Biologics, first allowed patent ... adds to the Company,s extensive C. difficile ...
(Date:10/22/2014)... , Oct. 22, 2014 Nuvilex, Inc. ... approximately 400 million people worldwide are living with diabetes, ... people by 2030.  The global market for diabetes treatments ... approximately 330,000 people worldwide died from pancreatic cancer.  Pancreatic ... due to cancer in the United States ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 ... enterprise, announced today that rare disease expert John ... president, research. Dr. McKew brings more than two decades ... at the National Institutes of Health, Wyeth Research and ... McKew will lead aTyr,s efforts to expand and translate ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
... WA, May 1 /PRNewswire-FirstCall/ - Oncothyreon Inc. ... filed an investigational new,drug (IND) application with ... a small molecule phosphatidylinositol-3-kinase (PI-3-kinase),inhibitor for the ... plans to initiate a Phase 1 clinical ...
... produced tiny liquid crystal devices with electrodes made from ... computer and TV displays based on this technology. , ... Dr Kostya Novoselov and colleagues from The School of ... report on the use of graphene as a transparent ...
... SAN DIEGO, April 30 Anadys Pharmaceuticals,Inc. (Nasdaq: ... improving,patient care by developing novel medicines in the ... financial results and highlights for the first,quarter ended ... in both of our development programs,during the first ...
Cached Biology Technology:Oncothyreon files investigational new drug application for PX-866 oncology compound 2Oncothyreon files investigational new drug application for PX-866 oncology compound 3Graphene-based gadgets may be just years away 2Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 2Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 3Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 4Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 5Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 6Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 7Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 8
(Date:10/17/2014)... is available in German . ... very few drugs. When treating overdoses, doctors are often limited ... difficult if there is a combination of drugs involved. So ... accidentally swallows his grandmother,s pills? ETH professor Jean-Christophe Leroux from ... find an answer to this question. "The task was to ...
(Date:10/16/2014)... are anything but sustainable: environmental damage to soil ... increasingly evident. Despite their disadvantages, however, monocultures remain ... the sole possibility of achieving higher yields in ... an ecology professor at the University of Zurich, ... forestry. After all, a new study carried out ...
(Date:10/15/2014)... assess the pandemic risk from strains of influenza virus ... allow ourselves to become complacent that the most substantial ... scientists. , Influenza pandemics arise when a new virus ... widespread immunity – spreads in the human population. There ... years, the worst of which – the 1918 Spanish ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2
... Researchers at the Hebrew University of Jerusalem have discovered ... utilizing human embryonic stem cells. Their work paves the ... stem cell therapy. Human embryonic stem cells ... the mature human body (and are hence defined as ...
... people are alike." Yet when we consider the thousands of ... it is remarkable how much alike we are. ... but a general property of life. Biologists have long pondered ... great variation in genetics as well as environmental conditions. ...
... for Research Resources (NCRR), part of the National ... up to an estimated $122 million over the ... (IDeA) Networks of Biomedical Research Excellence (INBRE) in ... and sharing of research resources and expertise, these ...
Cached Biology News:Hebrew University researchers neutralize tumor growth in embryonic stem cell therapy 2Researchers find snippet of RNA that helps make individuals remarkably alike 2NIH grants $122 million in Institutional Development Awards 2NIH grants $122 million in Institutional Development Awards 3
... The powerful solution for all plate washing ... format. ,The PW 384 provides an ... field of Drug Discovery (Assay development, Screening or ... speed ,The PW 384 has set ...
... Model 1575 immunowash microplate washer, 100-240 V, ... have flat-, U-, or V-bottom wells. This ... needle positions to an accuracy of 0.1 ... overflow washing. It can store up to ...
... a compact benchtop and stackable multi-function ... with a large display screen to ... Air circulation inside to evenly distribute ... be easily calibrated from the microprocessor ...
... compact benchtop and stackable multi-function incubator. ... a large display screen to accurately ... circulation inside to evenly distribute temperature ... easily calibrated from the microprocessor controller. ...
Biology Products: